SCM
URGN icon

Stonepine Capital Management’s UroGen Pharma URGN Stock Holding History

Stonepine Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-333,400
Closed -$3.69M – 84
2025
Q1 		$3.69M Buy
333,400
+9,076
+3% +$96.8K 3.59% 6
2024
Q4 		$3.45M Buy
324,324
+43,979
+16% +$527K 2.79% 13
2024
Q3 		$3.56M Buy
+280,345
New +$4.16M 2.25% 14
2023
Q3 		– Sell
-448,508
Closed -$4.64M – 26
2023
Q2 		$4.64M Sell
448,508
-253,027
-36% -$2.79M 1.67% 15
2023
Q1 		$6.48M Sell
701,535
-603,412
-46% -$5.55M 2.17% 12
2022
Q4 		$11.6M Buy
1,304,947
+180,727
+16% +$1.71M 4.87% 7
2022
Q3 		$9.35M Buy
1,124,220
+13,170
+1% +$109K 4.21% 7
2022
Q2 		$9.1M Buy
1,111,050
+842,217
+313% +$5.78M 4.23% 9
2022
Q1 		$2.34M Buy
+268,833
New +$2.1M 0.97% 20

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Stonepine Capital Management's URGN Position: Q2 2025 in Review

Stonepine Capital Management sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 333,400 shares — an estimated $3.69M sold.

Stonepine Capital Management first reported a position in URGN in Q1 2022 and held it in 9 quarters. The position peaked at $11.6M in Q4 2022. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

  • Stonepine Capital Management reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 333,400 UroGen Pharma shares in Q2 2025, an estimated $3.69M.
  • Stonepine Capital Management first reported a position in UroGen Pharma in Q1 2022 and held it in 9 quarters.
  • Stonepine Capital Management's UroGen Pharma position peaked at $11.6M in Q4 2022.
  • 150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on Stonepine Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.